ClinicalTrials.gg
CompletedNCT07292441GZR18-BWM-303Updated Nov 10, 2026

Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss

A Phase 3 interventional study of GZR18 injection and Placebo in Overweight or Obesity, sponsored by Gan & Lee Pharmaceuticals.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Gan & Lee Pharmaceuticals. · Phase 3, Interventional, and Treatment

Updated Nov 10, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing bofanglutide in Obesity — 3 open to participants now, 3 under way, 3 of them phase 3. bofanglutide · Obesity.

Enrollment
7th of 15
224 · median 140
Started
2026
with 3 others
Phase 3
5 of 15
3 open now
Registered
12th of 15
by date
Lead sponsor
9 of 15
Gan & Lee Pharmaceuticals.

Among the 15 studies testing bofanglutide in Obesity, this one is the 7th largest by enrollment, is one of 4 that started in 2026, is one of 5 in phase 3, and was the 12th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

3 of the 15 studies testing bofanglutide in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About bofanglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing bofanglutide in Obesity, or all of them as a file.
02

Study summary

This is a Phase 3 extension study conducted in subjects who have received GZR18 Injection once every 2 weeks (Q2W) for weight loss treatment for 52 weeks, aiming to explore the effect and safety of continuous injection of GZR18 Injection once every 4 weeks (Q4W) for 24 weeks on body weight.

In this study, it is planned to include subjects who have participated in the original study and completed the study contents of the original protocol. All subjects will maintain a regular diet and exercise lifestyle during the study.

03

Conditions studied

  • Overweight or Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 224 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Gan & Lee Pharmaceuticals. is the lead sponsor of 29 studies on the registry; 14 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who participated in the original study, completed the last dose at W50, EOT visit at W52 and safety follow-up visit at W55 of either original study, with last dose at W50 ≥ 24 mg (including blinded dose of placebo).
  2. Subjects with > 18.5 kg/m² at W55 of the original study and before randomization at Visit 2 (V2) of this study, who are assessed by the investigator as suitable for participating in this study.
  3. Subjects of with no birth plan from the signing of ICF to 8 weeks after the last dose, willingness to take effective measures, and no plan for sperm or ovum donation. Non-lactating women of childbearing potential (WOCBP) with a negative pregnancy test result before randomization at V2 in this study.
  4. Able to understand the procedures and methods of this study, willing and able to maintain a regular diet and exercise lifestyle during the study period, willing and able to undergo subcutaneous injections of the medicinal product (IMP), and willing to sign the ICF voluntarily.

    -

Exclusion criteria

Exclusion Criteria:

  1. Subjects who used Semaglutide (Wegovy®) in the original study.
  2. Subjects with a previous diagnosis of any type of diabetes mellitus (excluding gestational diabetes mellitus).
  3. Subjects with FPG ≥ 7.0 mmol/L or ≥ 6.5% in the central laboratory test at W52 visit of the original study.
  4. Subjects who plan to participate in another clinical study of an medicinal product or device, or receive drug or non-drug therapies that affect body weight (excluding diet and exercise control) before completing all scheduled assessments in this clinical study.
  5. Subjects with any other factors (including but not limited to previous compliance in the original study) that may affect the efficacy or safety evaluation of this study as judged by the investigator.

    -

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
224 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Other: Placebo

  • Experimental
    GZR18 injection Dose1

    Drug: GZR18 injection

  • Experimental
    GZR18 injection Dose2

    Drug: GZR18 injection

  • Experimental
    GZR18 injection Dose3

    Drug: GZR18 injection

Interventions

  • Used as specified in the protocol

  • OtherPlacebo

    Administered the same volume as GZR18

07

What researchers measure

Primary outcomes

  1. Percent change (%) from baseline in body weight

    Time frame: from Week 0 (W0) to Week 24 (W24)

Secondary outcomes

  1. Changes from baseline in weight;

    Time frame: from Week 0 (W0) to Week 24 (W24)

  2. Changes from baseline body mass index (BMI);

    Time frame: from Week 0 (W0) to Week 24 (W24)

  3. Changes from baseline in waist circumference, hip circumference, and waist-hip ratio (waist circumference/hip circumference);

    Time frame: from Week 0 (W0) to Week 24 (W24)

  4. Changes from baseline in hemoglobin A1c (HbA1c) ;

    Time frame: from Week 0 (W0) to Week 24 (W24)

  5. Changes from baseline in fasting plasma glucose (FPG);

    Time frame: from Week 0 (W0) to Week 24 (W24)

  6. Changes from baseline in blood pressure (SBP and DBP);

    Time frame: from Week 0 (W0) to Week 24 (W24)

  7. Changes from baseline in total cholesterol (TC);

    Time frame: from Week 0 (W0) to Week 24 (W24)

  8. Changes from baseline in low-density lipoprotein cholesterol (LDL-C);

    Time frame: from Week 0 (W0) to Week 24 (W24)

  9. Changes from baseline in high-density lipoprotein cholesterol (HDL-C);

    Time frame: from Week 0 (W0) to Week 24 (W24)

  10. Changes from baseline in triglyceride (TG);

    Time frame: from Week 0 (W0) to Week 24 (W24)

  11. Changes from baseline in free fatty acids.

    Time frame: from Week 0 (W0) to Week 24 (W24)

  12. Treatment-Emergent Adverse Events (TEAEs);

    Time frame: from Week 0 (W0) to Week 25 (W25)

  13. Treatment-Emergent Serious Adverse Events (TESAEs);

    Time frame: from Week 0 (W0) to Week 25 (W25)

  14. Pulse rate;

    Time frame: from Week 0 (W0) to Week 25 (W25)

  15. Lipase;

    Time frame: from Week 0 (W0) to Week 25 (W25)

  16. Amylase;

    Time frame: from Week 0 (W0) to Week 25 (W25)

  17. Calcitonin

    Time frame: from Week 0 (W0) to Week 25 (W25)

  18. The scores of Patient Health Questionnaire-9

    the highest/worst score during the trial (the higher scores mean a worse outcome

    Time frame: from Week 0 (W0) to Week 25 (W25)

  19. GZR18 anti-drug antibody (ADA) and neutralizing antibody (NAb);

    Time frame: from Week 0 (W0) to Week 25 (W25)

  20. Cross reaction between GZR18 ADA and endogenous glucagon-like peptide-1 (GLP-1).

    Time frame: from Week 0 (W0) to Week 25 (W25)

08

Study locations

1 site
  • Study site 01
    Beijing, Beijing Municipality Beijing, China
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2026 to primary completion in Sep 2026, 8 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 8 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Sep 2027 → Sep 2026 and completion Oct 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Dec 18, 2025
StartActual
Jan 22, 2026
Primary completionActual
Sep 22, 2026was Sep 2027
CompletionActual
Sep 22, 2026was Oct 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 10, 2026
Sites
1 site removed
Show 1 removed
  • Study site 01 · Beijing, China
Nov 10, 2026
Primary completion
Sep 2027→Sep 22, 2026 (actual)
Nov 10, 2026
Study completion
Oct 2027→Sep 22, 2026 (actual)
Nov 10, 2026
Enrollment
500 (estimated)→224 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Recruiting→Completed
    1 site removed
    Show 1 removed
    • Study site 01 · Beijing, China
    Primary completion Sep 2027→Sep 22, 2026 (now actual)
    Study completion Oct 2027→Sep 22, 2026 (now actual)
    Enrollment 500 (estimated)→224 (actual)
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07292441
Responsible party
Sponsor
First posted
Dec 18, 2025
Start date
Jan 22, 2026
Primary completion
Sep 22, 2026
Completion
Sep 22, 2026
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bofanglutide

Start the discussion